Treating Heavy Periods in People with Bleeding Disorders
Official title: Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study
Funded at Oregon Health & Science University · NIH-11193531 · Data updated 2026-11-12
This project compares two hormone treatments to help young people with bleeding disorders manage heavy periods and improve their quality of life.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project start | September 15, 2024 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $524,372 |
| NIH project number | 5R01HL173767-02 |
| Project ID | NIH-11193531 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adolescents and young adults with heavy menstrual bleeding and a diagnosed heritable bleeding disorder who are considering starting hormonal menstrual suppression.
✕Less likely to help
Patients who do not experience heavy menstrual bleeding or do not have a bleeding disorder would not directly benefit from this specific research.
What this research studies
Heavy menstrual bleeding is common among adolescents and young adults with a bleeding disorder and can negatively impact their daily life and overall health. While effective treatments exist to lessen bleeding and improve quality of life, they haven't been specifically studied in individuals with bleeding disorders, so we don't know how well they work for this group. This project will involve 300 adolescents and young adults with heavy periods and a diagnosed bleeding disorder who are choosing to start a progestin treatment. We will compare the effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUD) versus daily oral norethindrone acetate (NETA) over six months. The goal is to see which treatment best reduces bleeding, improves quality of life, and helps restore iron levels.
Why it matters
Potential benefit: If successful, this research could provide clear guidance on the most effective hormonal treatments for heavy periods in young people with bleeding disorders, significantly improving their health and daily lives.
How similar studies have gone: While progestin treatments are known to reduce heavy menstrual bleeding, their specific effectiveness and impact on diagnostic testing in individuals with bleeding disorders have not been thoroughly studied.
Where this research is happening
-
Oregon Health & Science University
Portland, United States Active
Researchers
- Principal investigator: Baldwin, Maureen — Oregon Health & Science University
- Study coordinator: Baldwin, Maureen
Related research
Other NIH-funded projects on the same topics.
-
Direct measurement of RhD sensitization after early-pregnancy bleeding
This study tests how often Rh immunoglobulin given after bleeding in early pregnancy prevents RhD sensitization in pregnant people.
-
EpiMAX: a new injectable gel that stops GI bleeding quickly and for days
A new injectable hydrogel with epinephrine-loaded microparticles is designed to plug GI bleeds and provide immediate and lasting hemostasis for about 72 hours.
-
Dynamic risk tools to prevent blood clots and bleeding in cancer patients
A new AI-based approach will predict who among people with cancer starting treatment is at higher risk for blood clots or dangerous bleeding, helping doctors tailor preventive care.
-
Bleeding and Platelet Problems in Ehlers-Danlos Syndrome
This NIH grant looks at why people with Ehlers-Danlos syndrome bleed more and how platelet function is involved, with goals that could lead to better care during surgery or emergencies.
-
Long-acting RNA therapy to control fibrinolysis and reduce bleeding
A new RNA treatment delivered in lipids aims to slow down fibrinolysis and lessen bleeding for people with bleeding disorders or severe hemorrhage.
-
Thrombosis and Bleeding Risk in Medical Inpatients
A patient-facing program to better predict who is at risk for blood clots or bleeding during and after hospital stays, and to tailor prevention accordingly.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.